User:Mr. Ibrahem/Nilotinib

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Nilotinib
Clinical data
Trade namesTasigna, others
Other namesAMN107
AHFS/Drugs.comMonograph
MedlinePlusa608002
License data
Pregnancy
category
  • AU: D
Routes of
administration		By mouth
Drug classBcr-Abl tyrosine kinase inhibitor[1]
Legal status
Legal status
Pharmacokinetic data
Bioavailability30%[2]
Protein binding98%[2]
MetabolismLiver (mostly CYP3A4-mediated)[2]
Elimination half-life15-17 hours[2]
ExcretionFaeces (93%)[2]
Identifiers
  • 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)- 5-(trifluoromethyl)phenyl]-3- [(4-pyridin-3-ylpyrimidin-2-yl) amino]benzamide
Chemical and physical data
FormulaC28H22F3N7O
Molar mass529.527 g·mol−1
3D model (JSmol)
  • Cc1ccc(cc1Nc2nccc(n2)c3cccnc3)C(=O)Nc4cc(cc(c4)n5cc(nc5)C)C(F)(F)F
  • InChI=1S/C28H22F3N7O/c1-17-5-6-19(10-25(17)37-27-33-9-7-24(36-27)20-4-3-8-32-14-20)26(39)35-22-11-21(28(29,30)31)12-23(13-22)38-15-18(2)34-16-38/h3-16H,1-2H3,(H,35,39)(H,33,36,37) checkY
  • Key:HHZIURLSWUIHRB-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Nilotinib, sold under the brand name Tasigna, is a medication used to treat chronic myelogenous leukemia (CML) which has the Philadelphia chromosome.[3] It may be used both in initial cases of chronic phase CML as well as in accelerated and chronic phase CML that has not responded to imatinib.[3][1] It is taken by mouth.[1]

Common side effects may include low platelets, low white blood cells, anemia, rashes, vomiting, diarrhea, and joint pains.[1] Other serious side effects may include QT prolongation, sudden death, pancreatitis, and liver problems.[1] It is not safe for use during pregnancy.[1] Nilotinib is a Bcr-Abl tyrosine kinase inhibitor and works by interfering with signalling within the cancer cell.[1]

Nilotinib was approved for medical use in the United States in 2007.[1] It is on the World Health Organization's List of Essential Medicines.[5] In the United Kingdom it costs the NHS £2,433 per month as of 2018.[6] In the United States this amount costs US$14,368 as of 2019.[7]

References[edit]

  1. ^ a b c d e f g h i "Nilotinib Monograph for Professionals". Drugs.com. Archived from the original on 14 July 2021. Retrieved 14 November 2019.
  2. ^ a b c d e "Tasigna (nilotinib) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Archived from the original on 17 July 2021. Retrieved 25 January 2014.
  3. ^ a b c "Nilotinib". National Cancer Institute. 1 February 2008. Archived from the original on 14 July 2021. Retrieved 14 November 2019.
  4. ^ "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 25 November 2020. Retrieved 10 September 2020.
  5. ^ "World Health Organization model list of essential medicines: 21st list 2019" (Document). 2019. hdl:10665/325771. {{cite document}}: Cite document requires |publisher= (help)
  6. ^ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 960. ISBN 9780857113382.
  7. ^ "Tasigna Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 24 December 2019. Retrieved 14 November 2019.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Nilotinib&oldid=1077401997"